Kite Pharma (KITE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kite Pharma (KITE) Q4 Report Illustrates 'Clear Vision', Stifel Says
March 26, 2015 4:54 PM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $83 price target on Kite Pharma (NASDAQ: KITE) following Q4 results, saying the company's action "speak loud and clear"
Shrader commented, "Kite reported 4Q14 results this morning and summarized the years results. The... More
